TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change from Baseline Type-2 Diabetes Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Metabolic Syndrome Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes to blood pressure, smoking rate, serum cholesterol, body mass index and blood glucose from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with stroke
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with systemic embolic event
Endpoint domain: Mortality/survival
Primary endpoint: Body Mass Index for age and gender z-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Height for age and gender z-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Undernutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of tumor-antigen specific T cell immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ovarian volume (female infants)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ovarian follicle count (female infants)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Testes volume (male infants)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage improvement of PASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Child functioning
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Trichotillomania Scale for Children-Chile and Parent Versions (TSC-C & TSC-p)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acceptance and Action Questionnaire for Trichotillomania (AAQ-TTM)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Warwick-Edinburgh Mental Well-being Scale (WEBWMS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants with bronchospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants with laryngospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants with apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of body fat percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Constant Shoulder Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with somatic BRCA mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of patients with homologous recombination repair deficiencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Levels of PI3K/Akt pathway expression per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Guidance of further diagnostic or therapeutic procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Endurance Time (Minutes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of Action Observation Training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to Action Observation Training
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes of lipid parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnostic accuracy of residual breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accuracy in determining pregnancy status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Sterols in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carotid plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Frequency of Hypoglycaemic Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Entrectinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUCinf) of Entrectinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUClast) of Entrectinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative Average Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of cytotoxic T lymphocytes (CD8+ cells)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in heat-pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Product performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ability to use the Magnap device
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: CGM System performance accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PROMIS Global Health Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Knee Injury and Osteoarthritis Outcome Score Jr.
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Daily dose of Mesalazine
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent of Sphygmo Readings Within 5mmHg, 10mmHg, and 15mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amblyopia Risk Factor prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody response to influenza vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Physician diagnosed respiratory infection incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Antibody response to second hepatitis B vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Systemic Inflammatory bio-markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with completed appointments in telemedicine cohort
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient and Provider Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Provider Experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Success of levator resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of new micro- and macro-embolic lesions on cerebral MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Free plasma hydrogen sulfide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Survival at 26 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Neutrophil numbers in nasal lavage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients who complete treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Average length of treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tinnitus Functional Index (TFI) change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants With Investigator's Global Assessment (IGA) Scale Success at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline on Community Balance and Mobility (CB&M)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reversal rate of metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Extracorporeal circuit coagulation events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative Pulmonary Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum (peak) plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevention of excessive bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Glycated Hemoglobin (A1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDL-Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum tolerated dose (MTD) of ribociclib and gemcitabine hydrochloride
Endpoint domain: Adverse events/effects
Primary endpoint: Cerebrovascular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Peripheral vascular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Neutropenic Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Preparedness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Disease Activity Score (3 Variables)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and Severity of TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Serious TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and Severity of Adverse Events of Special Interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical rebleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perioperative blood transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Accuracy of temperature monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of DLTs during the first cycle of treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Successful Telemedicine Encounter Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Slow vital capacity (SVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hand held dynamometry (HHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in the combined symptom medication score (CSMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Gut Microbiota Composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pulmonary function testing (PFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of missed injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Levels on Four Point Category Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Levels on Heft-Parker Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Levels on Visual Analog Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local relapse
Endpoint domain: Mortality/survival
Primary endpoint: Urine levels of biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change on pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of JNJ-39393406
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in cognition in elderly and young healthy participants
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Successful closure of myelomeningocele
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline in UPDRS subscale III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Unexpected postoperative symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of minimally invasive hysterectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complete Response, Acute Phase (Day 1), Cycle 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Response, Delayed Phase (Days 2 to 11), Cycle 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Children's Global Assessment Scale (CGAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Family Assessment Device (FAD) (Parent-rated)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Parental Sense of Competency (PSOC)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tumour mutational burden (TMB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Genetic mutations associated with susceptibility to Toxoplasma gondii
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Recovery
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Endpoint subdomain: null
Primary endpoint: Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity of 18F-Fluciclovine-PET/MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificity of 18F-Fluciclovine-PET/MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity of 18F-FDG-PET/MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificity of 18F-FDG-PET/MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean systemic pressure variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: exacerbations of COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AUC0-tz of Empagliflozin in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC0-tz of Metformin in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of Empagliflozin in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with any Serious Adverse Event or Treatment-Emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Gene expressions of cumulus cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum levels of carcinoembryonic antigen (CEA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of carbohydrate antigen 19-9 (CA19-9)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of carbohydrate antigen 125 (CA125)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of reloads during the surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ratio of patients with 2 or more reloads
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Circulating bile acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gross residence time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast sensitivity time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically meaningful improvement in bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hyperprolactinemia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Stent length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Predicted stent diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adverse Events related to treatment of nivolumab in combination with relatlimab
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Events related to treatment of nivolumab in combination with ipilimumab
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of recruitment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of the procedure to patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ease of CT acquisition
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sleep Onset Latency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Status of primary anxiety disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-HT toxicity evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Severe Hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Scapular Kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Humeral Translations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Safety profile of AZD1775
Endpoint domain: Adverse events/effects
Primary endpoint: Status of onset of Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Vector density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sporozoite rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Entomological inoculation rate EIR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemagglutination inhibition assay (HAI) titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Theoretical hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Esophageal variceal re-bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Unplanned cardiovascular hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: frequency of suicide attempts
Endpoint domain: Mortality/survival
Primary endpoint: Incidence rate of TVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety (Adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory testing
Endpoint domain: Adverse events/effects
Primary endpoint: Local Catheter Site Infection (LCSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Seroconversion rates of EV71 neutralizing antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cognitive measures - performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: cognitive measures - reaction times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: endocannabinoid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: brain activations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EORTC PATSAT-C33 questionnaire validation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: EORTC OUT-PATSAT7 questionnaire validation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of Tics Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Stress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Required Blood Transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ocular surface disease index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of ATTRm mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes